{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:23:13Z","timestamp":1791217393087,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.canlet.2013.08.040","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T15:04:03Z","timestamp":1378134243000},"page":"104-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells"],"prefix":"10.1016","volume":"342","author":[{"given":"Bin","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quancheng","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Mankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Hornicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2013.08.040_b0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2353\/ajpath.2008.070284","article-title":"A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas","volume":"172","author":"Matushansky","year":"2008","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.canlet.2013.08.040_b0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2008-1038310","article-title":"World health organization classification of bone and soft tissue tumors: modifications and implications for radiologists","volume":"11","author":"Murphey","year":"2007","journal-title":"Seminars in Musculoskeletal Radiology"},{"key":"10.1016\/j.canlet.2013.08.040_b0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"Sleijfer","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.canlet.2013.08.040_b0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"Van Glabbeke","year":"1999","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2013.08.040_b0025","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1245\/s10434-011-1794-0","article-title":"Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis","volume":"18","author":"Ghadimi","year":"2011","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.canlet.2013.08.040_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1582-4934.2009.00983.x","article-title":"Imatinib treatment for gastrointestinal stromal tumour (GIST)","volume":"14","author":"Lopes","year":"2010","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.canlet.2013.08.040_b0035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/modpathol.2011.148","article-title":"Involvement of the PI3K\/Akt pathway in myxoid\/round cell liposarcoma","volume":"25","author":"Demicco","year":"2012","journal-title":"Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology, Inc."},{"key":"10.1016\/j.canlet.2013.08.040_b0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4161\/cbt.7.8.6301","article-title":"Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy","volume":"7","author":"Dass","year":"2008","journal-title":"Cancer Biology and Therapy"},{"key":"10.1016\/j.canlet.2013.08.040_b0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/path.2564","article-title":"C-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme","volume":"218","author":"Snyder","year":"2009","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.canlet.2013.08.040_b0050","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2013.783911","article-title":"Emerging drug profile: cyclin-dependent kinase inhibitors","author":"Blachly","year":"2013","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.canlet.2013.08.040_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","author":"Dickson","year":"2013","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2013.08.040_b0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006353008903","article-title":"Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials","volume":"17","author":"Senderowicz","year":"1999","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.canlet.2013.08.040_b0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10637-010-9563-7","article-title":"A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors","volume":"30","author":"Ramaswamy","year":"2012","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.canlet.2013.08.040_b0070","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.1200\/JCO.2004.01.0660","article-title":"S. Children\u2019s Oncology Group, Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"23","author":"Whitlock","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2013.08.040_b0075","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/nbm.1674","article-title":"Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS","volume":"24","author":"Darpolor","year":"2011","journal-title":"NMR in Biomedicine"},{"key":"10.1016\/j.canlet.2013.08.040_b0080","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/ijc.22820","article-title":"Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing\u2019s family tumor cells","volume":"121","author":"Li","year":"2007","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"key":"10.1016\/j.canlet.2013.08.040_b0085","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1158\/1078-0432.CCR-12-1157","article-title":"Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation","volume":"18","author":"Duan","year":"2012","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.040_b0090","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1074\/jbc.M206427200","article-title":"The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis","volume":"278","author":"Shi","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.canlet.2013.08.040_b0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1471-4159.2003.02119.x","article-title":"Cyclin-dependent kinase 11p110 and casein kinase 2 (CK2) inhibit the interaction between tyrosine hydroxylase and 14-3-3","volume":"88","author":"Sachs","year":"2004","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.canlet.2013.08.040_b0100","article-title":"CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110)","author":"Choi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.08.040_b0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10753-012-9450-9","article-title":"The functional interaction between CDK11p58 and beta-1,4-galactosyltransferase I involved in astrocyte activation caused by lipopolysaccharide","volume":"35","author":"Liu","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.canlet.2013.08.040_b0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.embor.7400639","article-title":"The PITSLRE\/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation","volume":"7","author":"Petretti","year":"2006","journal-title":"EMBO Reports"},{"key":"10.1016\/j.canlet.2013.08.040_b0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbrc.2011.02.132","article-title":"CDK11p46 and RPS8 associate with each other and suppress translation in a synergistic manner","volume":"407","author":"Hao","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.canlet.2013.08.040_b0120","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1074\/jbc.M210057200","article-title":"CDK11 complexes promote pre-mRNA splicing","volume":"278","author":"Hu","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.canlet.2013.08.040_b0125","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1074\/jbc.M109755200","article-title":"PITSLRE p110 protein kinases associate with transcription complexes and affect their activity","volume":"277","author":"Trembley","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.canlet.2013.08.040_b0130","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cellsig.2005.02.005","article-title":"Role of CDK\/cyclin complexes in transcription and RNA splicing","volume":"17","author":"Loyer","year":"2005","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.canlet.2013.08.040_b0135","doi-asserted-by":"crossref","first-page":"15786","DOI":"10.1016\/S0021-9258(17)40749-6","article-title":"Molecular cloning and expression of alternatively spliced PITSLRE protein kinase isoforms","volume":"269","author":"Xiang","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.canlet.2013.08.040_b0140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jor.22230","article-title":"Targeting hedgehog-GLI-2 pathway in osteosarcoma","volume":"31","author":"Yang","year":"2013","journal-title":"Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society"},{"key":"10.1016\/j.canlet.2013.08.040_b0145","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","article-title":"MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data","volume":"29","author":"Binh","year":"2005","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.canlet.2013.08.040_b0150","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/jcp.2009.070201","article-title":"Can MDM2 and CDK4 make the diagnosis of well differentiated\/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours","volume":"62","author":"Aleixo","year":"2009","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/j.canlet.2013.08.040_b0155","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-07-0584","article-title":"Gene expression profiling of liposarcoma identifies distinct biological types\/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma","volume":"67","author":"Singer","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.040_b0160","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nature Genetics"},{"key":"10.1016\/j.canlet.2013.08.040_b0165","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1)","volume":"104","author":"Schwartz","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.canlet.2013.08.040_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/MCB.15.1.1","article-title":"PITSLRE protein kinase activity is associated with apoptosis","volume":"15","author":"Lahti","year":"1995","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.canlet.2013.08.040_b0175","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1128\/MCB.24.8.3188-3197.2004","article-title":"Failure to proliferate and mitotic arrest of CDK11(p110\/p58)-null mutant mice at the blastocyst stage of embryonic cell development","volume":"24","author":"Li","year":"2004","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.canlet.2013.08.040_b0180","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/BJ20040848","article-title":"Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90","volume":"384","author":"Mikolajczyk","year":"2004","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.canlet.2013.08.040_b0185","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-11-3203","article-title":"The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial","volume":"18","author":"Luke","year":"2012","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.040_b0190","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-07-1218","article-title":"Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors","volume":"13","author":"Fornier","year":"2007","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.040_b0195","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00280-010-1269-1","article-title":"A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol","volume":"66","author":"Dickson","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.canlet.2013.08.040_b0200","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1158\/1078-0432.CCR-09-1502","article-title":"Phase I study of flavopiridol with oxaliplatin and fluorouracil\/leucovorin in advanced solid tumors","volume":"15","author":"Rathkopf","year":"2009","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.040_b0205","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1158\/1078-0432.CCR-04-2651","article-title":"A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol","volume":"11","author":"Shah","year":"2005","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.040_b0210","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.celrep.2012.09.027","article-title":"Cdk11-cyclinL controls the assembly of the RNA polymerase II mediator complex","volume":"2","author":"Drogat","year":"2012","journal-title":"Cell Reports"},{"key":"10.1016\/j.canlet.2013.08.040_b0215","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1074\/jbc.M708188200","article-title":"Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection","volume":"283","author":"Loyer","year":"2008","journal-title":"The Journal of Biological Chemistry"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513006253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513006253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:53:30Z","timestamp":1646477610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513006253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0304383513006253"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.08.040","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.08.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}